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Abstract 
Background: Invasive candidiasis (IC) is a frequent and life-threatening infection in critically ill patients. The aim of 
this study was to evaluate the epidemiology of IC and the antifungal susceptibility of etiological agents in patients 
admitted to our surgical intensive care unit (SICU) in Spain.
Methods: We designed a prospective, observational, single center, population-based study in a SICU. We included 
all consecutive adult patients (≥18 years old) who had documented IC, either on admission or during their stay, 
between January 2012 and December 2013.
Results: There were a total of 22 episodes of IC in the 1149 patients admitted during the 24-month study. The overall 
IC incidence was 19.1 cases per 1000 admissions. Thirteen cases of IC (59.1 %) were intra-abdominal candidiasis (IAC) 
and 9 (40.9 %) were candidemias. All cases of IAC were patients with secondary peritonitis and severe sepsis or septic 
shock. The overall crude mortality rate was 13.6 %; while, it was 33 % in patients with candidemia. All patients with IAC 
survived, including one patient with concomitant candidemia. The most common species causing IC was Candida 
albicans (13; 59.1 %) followed by Candida parapsilosis (5; 22.7 %), and Candida glabrata (2; 9.1 %). There was also one 
case each (4.5 %) of Candida krusei and Candida tropicalis. Thus, the ratio of non-C. albicans (9) to C. albicans (13) was 
1:1.4. There was resistance to fluconazole and itraconazole in 13.6 % of cases. Resistance to other antifungals was 
uncommon.
Conclusions: Candida parapsilosis was the second most common species after C. albicans, indicating the high preva-
lence of non-C. albicans species in the SICU. Resistance to azoles, particularly fluconazole, should be considered when 
starting an empirical treatment. Although IAC is a very frequent form of IC in critically ill surgical patients, prompt 
antifungal therapy and adequate source control appears to lead to a good outcome. However, our results are closely 
related to our ICU and any generalization must be taken with caution. Therefore, further investigations are needed.
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Background
Approximately 15 % of health-care associated infections 
are caused by fungi and Candida accounts for 70–90 % of 
all invasive infections. Candida spp. are included in the 
10 most common microorganisms causing bloodstream 
infections (BSI). North American and European studies 
showed that yeasts belonging to genus Candida ranged 
from the fourth to tenth most common cause of BSI [1]. 
On the other hand, 30–40  % of episodes of recurrent 
gastrointestinal tract perforation or acute necrotizing 
pancreatitis are complicated by intra-abdominal candidi-
asis (IAC) [2]. However, the diagnosis of non-candidemic 
invasive candidiasis (IC) remains elusive in the majority 
of patients. In fact, neither the guidelines from the Infec-
tious Diseases Society of America [3] nor the European 
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consensus [4] provided any clarification on IAC; while, 
epidemiological data over the last decades have shown 
than non-candidemic IC, which is mostly peritonitis, is a 
frequent and life-threatening complication in critically ill 
surgical patients [5]. Due to the poor outcome associated 
with IC in critically ill patients, an understanding of local 
epidemiologic trends and the antifungal susceptibility of 
etiological agents is crucial. The main goal of this study 
was to evaluate the epidemiology of IC in our surgical 
intensive care unit (SICU). Additionally, we evaluated 
in vitro susceptibility of isolates and outcome of IC in our 
SICU during a 2-year period.
Methods
We designed a prospective, observational, single center 
study between January 2012 and December 2013. All con-
secutive adult patients (≥18 years old) who had documented 
IC, either on admission or during their stay, were enrolled. 
The local ethics committee (Instituto de Investigación Sani-
taria, INCLIVA) approved the protocol. Informed consent 
was obtained from patients or their representative.
The definition of IC was the recovery of yeast from 
blood culture or other normally sterile site. Candidemia 
was considered to be catheter-related if a catheter tip 
culture yielded the same yeast isolated in the blood-
stream. Candida colonization was considered unifocal 
when Candida species were isolated from one non-steril 
site and considered multifocal when Candida species 
were simultaneously isolated from at least two differ-
ent non-steril sites, even if two different Candida spe-
cies were isolated [6]. Corticosteroid treatment was 
defined as exposure to a 10  mg/day prednisone equiva-
lent for ≥30 days. Adequate source control was defined 
as removal of any preexisting central vein catheters or 
documented surgical or radiologic procedures to drain 
abscesses or other fluid collections thought to be the 
source of Candida infection within 24 h of the onset of 
infection. The severity and organ dysfunction at the IC 
diagnosis were computed by the sequential organ failure 
assessment (SOFA) score [7]. Antifungal treatment was 
considered adequate if the recommended dose of an anti-
fungal drug was administered within 48  h after sample 
collection for a susceptible Candida isolate [8], accord-
ing to the species-specific clinical breakpoint suggested 
by the Clinical Laboratory Standards Institute (CLSI) 
subcommittee [9]. The outcome variables were early 
(≤7 days) and late (8–30 days) mortality.
Laboratory procedures
Blood specimens and non-centrifuged peritoneal fluids 
obtained during surgery (one specimen/patient) were 
directly inoculated into two bottles of BACTEC media 
(PLUS aerobic/F and PLUS anaerobic/F; BD Diagnostics, 
Sparks, MD, USA), which were incubated for a maximum 
of 7 days, and analyzed using the automated continuous 
blood culture monitoring BACTEC FX system (BD Diag-
nostics). The broth was then sub-cultured on Sabouraud 
Dextrose Agar with Chloramphenicol (SC) when yeast 
growth was observed. For colonization purposes, phar-
yngeal and anal exudates were inoculated in Brain Heart 
Infusion Broth incubated at 37  °C for 24 or 48  h, and 
then sub-cultured on SC. Urine specimens were directly 
streaked onto SC. Cultured yeasts were identified based 
on the macro-microscopic features of the culture, germ 
tube test, and biochemical tests (VITEK® 2 system bio-
Mérieux, Inc. Hazelwood, MO, USA or API®/ID 32C bio-
Mérieux, Marcy l’Etoile, France).
Antifungal susceptibility tests were performed using 
Sensititre Yeast One® (TREK Diagnostic Systems Ltd.). 
The minimum inhibitory concentration (MIC) results 
for all antifungals, except for amphotericin B, were inter-
preted by taking into account the species-specific clinical 
breakpoint suggested by the CLSI [9]. In accordance with 
the literature data, a breakpoint ≤1 μg/ml was selected 
for amphotericin B to define the isolates as sensitive (S).
Statistical analysis
Continuous normally distributed data are expressed as 
the mean and standard deviation (SD) and compared 
using unpaired Student’s t test. Non-normally distributed 
data are expressed as the median and interquartile ranges 
(IQR) and compared using the Mann–Whitney U test. 
Categorical data are expressed as the number and per-
centage and compared using χ2 or the Fisher’s exact tests. 
In all comparisons, a p < 0.05 was considered to be statis-
tically significant. Data analysis was performed using the 
Statistical Package for the Social Sciences software.
Results
Baseline characteristics of the patients are shown in 
Table  1. Among 1149 patients consecutively admitted to 
our ICU during the 24-month survey, 22 patients with IC 
were identified. The overall IC incidence was 19.1 cases per 
1000 admissions. The most common predisposing factors 
for IC, present at the time of diagnosis, were central venous 
catheter (CVC) and urinary catheter presence (100 %), fol-
lowed by antibiotic therapy (95.4 %), mechanical ventilation 
(90.9  %), ICU stay ≥7  days (68.2  %), and total parenteral 
nutrition (63.6 %). The median age of the patients was 66 
(53.7–74.2) years, with 72.7  % males and 27.3  % females. 
The admitting diagnosis was surgical in 90.9 % (70 % intra-
abdominal) and medical in 9.1  % of cases. The median 
SOFA score at enrollment was 5 (3–6.2). In 2 cases (9.1 %), 
IC was already present at ICU admission, while it occurred 
during the ICU stay in 20 cases (90.9  %), with a median 
onset time of 20 days (5–37.5).
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Sites of infection and Candida species
Thirteen cases of IC (59.1  %) were IAC and nine 
(40.9 %) were candidemias. All cases of IAC occurred 
in patients with secondary peritonitis and severe sep-
sis or septic shock. All samples of peritoneal fluid 
were obtained surgically. The Candida species found 
are reported in Table  2, 13 cases of IC (59.1  %) were 
caused by Candida albicans (CA) and 9 (40.9  %) by 
non-Candida albicans (nCA) species (ratio nCA:CA 
was 1:1.4). Candida parapsilosis was the most preva-
lent nCA species (5; 22.7  %), followed by Candida 
glabrata (2; 9.1 %). A multifocal colonization was doc-
umented in eight (36.4 %) patients with IC. In 75 % of 
these cases, there was colonization by the same yeast 
species isolated from blood or peritoneal fluid. Cath-
eter removal was possible in all patients immediately 
after the onset of IC, and a tip culture was performed 
in all cases. Two cases (22.2  %) of candidemia were 
catheter-related. The duration of candidemia [median 
(IQR)] was: 7 (9.5–14.5) days (Table 1). In 20 (90.9 %) 
patients, the infectious process was a mixed infec-
tion caused by yeast and bacteria, with Gram-negative 
bacteria (68  %), especially Pseudomonas aeruginosa 
(32 %), being most common.
Antifungal susceptibility testing
All isolates were tested for in vitro antifungal susceptibil-
ity according to the CLSI breakpoints [9]. The results of 
antifungal resistance are shown in the Table  3. All iso-
lates were susceptible to amphotericin B, voriconazole, 
caspofungin, and posaconazole; while, 13.6 % of isolates 
were resistant to fluconazole (C. albicans, 1; C. glabrata, 
1; Candida krusei, 1) and itraconazole (C. albicans, 2; C. 
krusei, 1). In one patient, C. parapsilosis was resistant to 
Table 1 Baseline characteristics of  patients with  invasive 
candidiasis (IC)
CVC Central venous catheter, IQR interquartile range, LOS length of stay, SOFA 
sequential organ failure assessment
a In the two patients who developed invasive candidiasis prior to ICU admission, 
their SOFA score was calculated at ICU admission
Characteristics Yeast infection, n = 22
Age (years), median (IQR) 66 (53.7–74.2)
Male sex, n (%) 16 (72.7)
Comorbidities, n (%) 21 (95.4)
 Chronic renal failure, n (%) 3 (13.6)
 Diabetes mellitus, n (%) 7 (31.8)
 Solid tumor, n (%) 7 (31.8)
Steroid therapy, n (%) 0 (0)
Parenteral nutrition, n (%) 14 (63.6)
Mechanical ventilation, n (%) 20 (90.9)
Urinary catheter, n (%) 22 (100)
Central venous catheter (CVC), n (%) 22 (100)
CVC removed, n (%) 22 (100)
Yeast positivity in removed CVC, n (%) 2 (9.1)
Previous hospitalization, n (%) 16 (72.7)
Pre-IC diagnosis LOS (days), median (IQR) 20 (5–37.5)
LOS >7 days, n (%) 15 (68.2)
Admission typology –
 Surgical pathology, n (%) 20 (90.9)
 Medical pathology, n (%) 2 (9.1)
 Trauma, n (%) 0 (0)
Abdominal surgery, n (%) 14 (63.6)
SOFA scorea on IC diagnosis, median (IQR) 5 (3–6.2)
Empirical therapy duration (days), median (IQR) 10 (5–16.5)
Previous antibiotic therapy, n (%) 21 (95.4)
Concomitant bacterial infection, n (%) 20 (90.9)
Concomitant bacteremia, n (%) 9 (40.9)
Fungemia, n (%) 9 (40.9)
Fungemia duration (days), median (IQR) 7 (9.5–14.5)
Previous fungal invasive infection, n (%) 2 (9.1)
C. albicans species, n (%) 13 (59.1)
Fungal multifocal colonization, n (%) 8 (36.4)
Colonization and infection species  
coincidence, n (%)
6 (75)
Mortality (global), n (%) 3 (13.6)
 Early mortality (≤7 days), n (%) 2 (9.1)
 Late mortality (>7 days), n (%) 1 (4.5)
Mortality in presence of fungemia, n (%) 3 (33.3)
Mortality in absence of fungemia, n (%) 0 (0)
Table 2 Candida species in 22 patients with IC
Species Isolates, n (%)
C. albicans 13 (59.1)
C. parapsilosis 5 (22.7)
C. glabrata 2 (9.1)
C. tropicalis 1 (4.5)
C. krusei 1 (4.5)
Table 3 Antifungal resistances in  22 Candida isolates 
from patients with IC
Antifungal Resistance, n (%)
5-fluorocytosine 1 (4.5)
Amphotericin B 0 (0)
Fluconazole 3 (13.6)
Voriconazole 0 (0)
Caspofungin 0 (0)
Posaconazole 0 (0)
Micafungin 1 (4.5)
Anidulafungin 1 (4.5)
Itraconazole 3 (13.6)
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anidulafungin and micafungin with a MIC of 4 mg/L for 
both echinocandins.
Treatment
No patient was on antifungal prophylaxis at the time of 
IC diagnosis. Empirical therapy was started in 100 % of 
patients within 24  h of the onset of symptoms and the 
duration was 10 (5.0–16.5) days. The drugs empirically 
prescribed were echinocandins (86.4 %, 19 patients), fol-
lowed by fluconazole (13.6  %, 3 patients). In all cases, 
empirical therapy was confirmed as the target therapy. 
Eight patients (36.4  %) underwent de-escalation with 
fluconazole.
Patient outcome
Overall, the crude mortality rate was 13.6 %; while, it was 
33.3  % in patients with candidemia (two patients with 
C. albicans and one patient with C. parapsilosis). All 
patients with IAC survived, including one patient with 
concomitant candidemia. Early and late mortality were 
9.1 and 4.5  %, respectively. Data on the severity, organ 
dysfunction, lenght of stay in the SICU and mortality 
according to the type of IC are shown in the Table 4.
Discussion
We have reported an overall IC incidence of 19.1 
cases per 1000 admissions. This finding is higher than 
the data reported for Northern Europe (6.7–7.4 cases 
per 1000 admissions) [10, 11] or Italy (16.5 cases per 
1000 admissions) [12] and lower than those reported 
in other European countries (35.7–54 cases per 1000 
admissions) [13, 14]. We found that C. albicans was 
the leading agent (13 cases; 59.1  %), followed by C. 
parapsilosis (4 cases; 22.7  %) then C. glabrata (2 
cases; 9.1  %). Although C. albicans is still regarded 
as the most common species [3], there has been 
an increasing incidence of nCA infections with C. 
glabrata and C. parapsilosis [15–18]. In our country, 
a recent multicenter study about candidemias dem-
onstrated an increase in nCA infections in the ICU 
[19]. Our data confirm this increase and C. parapsi-
losis was the most common among the nCA species.
It is noteworthy that the resistance to itraconazole 
and, especially, fluconazole was 13.6 %. However, resist-
ance to echinocandins was low in our patients (Table 3). 
Only one patient (who survived) with C. parapsilosis 
was resistant to anidulafungin and micafungin, accord-
ing to the breakpoints used in our study [9], with a MIC 
of 4  mg/L for both antifungals. Nonetheless, in this 
case, anidulafungin was used empirically, improving 
the signs and symptoms of sepsis immediately after the 
onset of the treatment. There was clinical and microbio-
logical resolution in the following days and a successful 
outcome. The MIC values published recently [20] were 
higher than the MICs used in our study [9], and this 
might explain the patient’s good clinical response to 
treatment.
The most frequent IC in our patients was IAC 
(59.1 %). Previous studies have demonstrated that fun-
gal infections adversely affect the outcome of patients 
with peritonitis. In fact, isolation of Candida from 
peritoneal fluid has been associated with high mortal-
ity [21, 22]. In IAC, as in candidemias, the delay in the 
initiation of antifungal therapy is a major determinant 
of clinical outcome [23, 24]. It is striking that, in our 
study, all patients with IAC survived. It is likely that 
the prompt (within 24 h of IC onset) and appropriate 
antifungal therapy and adequate source control could 
explain these outcomes. There is sufficient evidence in 
the literature to support the strategy of early adminis-
tration of antifungal therapy and adequate source con-
trol in patients with IC [8, 25].
In the subgroup of patients with candidemia (n =  9), 
the CVC was removed in all cases, but the candidemia 
was catheter-related in only two cases (22.2 %). The mor-
tality rate in candidemic patients was 33.3 % (3 patients). 
In these patients, candidemia (2 C. albicans, 1 C. parap-
silosis) was considered primary, with an unknown origin. 
In fact, primary candidemia was recently identified as 
an independent risk factor for mortality in candidemic 
patients [19].
There are some limitations in our study. First, this 
is a single center study of a critically ill surgical patient 
population and our epidemiology cannot be extrapo-
lated to all settings. The second limitation is that the fre-
quency of colonization by Candida species was probably 
underestimated because surveillance cultures were not 
systematically screened. Finally, due to the small sam-
ple size (n  =  22) direct comparisons between the two 
groups of IC (IAC and candidemia) could not be reliably 
performed.
Table 4 Candidemia and intra-abdominal candidiasis (IAC) 
group characteristics
IQR interquartile range, SOFA sequential organ failure assessment
In all comparisons between groups there were no statistically significant 
differences (p > 0.05)
Characteristics Candidemia, n = 9 IAC, n = 13
SOFA score on diagnosis,  
median (IQR)
5.00 (4.5–7) 4 (3–6)
Length of stay in the SICU, days, 
median (IQR)
26.00 (6–40.5) 10 (5–31.5)
Mortality, n (%) 3 (33) 0 (0)
 Early mortality (≤7 days), n (%) 2 (22.2) 0 (0)
 Late mortality (>7 days), n (%) 1 (11.1) 0 (0)
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Conclusions
Our study confirmed the high prevalence of nCA spe-
cies in critically ill surgical patients and C. parapsilosis 
as the most common species after C. albicans. Resist-
ance to azoles, particularly fluconazole, should be 
considered when starting an empirical treatment. The 
most common IC was IAC in this study of critically ill 
surgical patients. Although the isolation of Candida 
spp. in peritoneal specimens of nosocomial peritoni-
tis has been suggested as an independent risk factor of 
mortality, all patients with IAC survived in this study. 
The prompt antifungal therapy and adequate source 
control in our patients likely explains their good out-
come. However, our results just reflect the state of the 
matter at our ICU and naturally can not be extrapo-
lated to other ICUs. Therefore, further investigation is 
necessary.
Key points
  • In surgical intensive care patients, the prevalence of 
non-Candida albicans species has increased in the 
last few years.
  • Resistance to fluconazole should be considered when 
initiating an empirical antifungal treatment in critical 
care surgical patients.
  • Intra-abdominal candidiasis is a very frequent form 
of invasive candidiasis in the critical care surgical set-
ting.
  • Prompt antifungal therapy and adequate source con-
trol might explain the good outcome of our patients 
with intra-abdominal candidiasis.
  • Additional larger multicenter studies are needed to 
confirm our findings.
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